中国医药科学Issue(12)：17-19,23,4.
替吉奥联合奥沙利铂一线治疗晚期食管癌的临床观察
A phase Ⅱ trial of S-1 plus oxaliplatin as first-line chemotherapy for advanced esophageal carcinoma
摘要
Abstract
Objective This study was to evaluate the efficacy and toxicity of SOX regimen as first-line chemotherapy for advanced esophageal carcinoma (AEC) patients.Methods Thirty-five patients with pathologically confirmed AEC were entered into the study. They received S-1 (60mg, bid, days 1 to 14) and oxaliplatin (130mg/m², day 1) every 3 weeks. Treatment efficacy was evaluated every six weeks based on the WHO standard. All patients received at least two cycles of therapy.Results Patients received a total of 113 cycles of treatment, and all were evaluable for efficacy and toxicity. The overall response rate was 62.86%. No complete response (CR) was achieved, 17 (48.57%) achieved partial responses (PRs), 5 (14.29%) had stable disease (SD), and 13 had progression disease (PD). The median time to progression (TTP) was 187 days and the median survival time (MST) was 287 days. Hematologic toxicity included 3 cases (8.57%) of grade Ⅲ~Ⅳ neutropenia, and two cases of grade Ⅲ~Ⅳ thrombocytopenia. The main non-hematologic toxicity included three cases of grade Ⅲ nausea/vomiting (8.57%).ConclusionSOX regimen is effective and well tolerated as first-line chemotherapy for AEC patients.关键词
食管癌/替吉奥/奥沙利铂Key words
Esophageal carcinoma/S-1/Oxaliplatin分类
医药卫生引用本文复制引用
郭经锋,吴锋,张铂,邢辉,王兵,彭静..替吉奥联合奥沙利铂一线治疗晚期食管癌的临床观察[J].中国医药科学,2015,(12):17-19,23,4.基金项目
广东省广州市番禺区科技计划项目（2013-Z03-16）。 （）
